简体中文

AC-10-核仁颗粒型

同义词 核仁斑点状 Nucleolar speckled
描述
间期细胞：核仁内呈现密集分布但彼此清晰可辨的颗粒状荧光。中期细胞：在染色质团块中，可见多达5对明亮的核仁组成体（NOR）。有丝分裂期细胞：胞质可能呈弱阳性反应。
Densely distributed but distinct speckles in the nucleoli of interphase cells. In metaphase cells, up to 5 bright pairs of the nucleolar organizer region (NOR) can be seen as speckles in the chromatin mass. The cytoplasm of mitotic cells may be slightly positive
抗原相关性 RNA聚合酶I，NOR-90/hUBF RNA polymerase I (RNApol-I), NOR90/hUBF

  • 临床相关性

    一级信息

    关于临床相关性和缩写列表

    Clinical Relevance

    First level information

    About Clinical Relevance & List of Abbreviations

  • ▶ AC-10核型可见于多种疾病状态，包括系统性硬化症（SSc）、雷诺现象、干燥病（SjD）及恶性肿瘤[1-7]。

    ▶ 若观察到AC-10核型，应考虑后续检测NOR90抗体；该抗原已包含于疾病特异性免疫检测（如系统性硬化症谱系检测）之中[3, 4]。
    ▶ NOR90抗体与副肿瘤性系统性硬化症（SSc）相关，同时也与SSc患者及特发性间质性肺炎患者的间质性肺病相关[8, 9]。
    ▶ 虽然AC-10核型可见于含RNA聚合酶III抗体的血清中，但这被认为是由于与RNA聚合酶I和/或RNA聚合酶II抗体的交叉反应性所致。RNA聚合酶III抗体也与AC-4与AC-5混合核型相关[10]；因此，若临床上怀疑SSc，建议进行RNA聚合酶III抗体的后续检测；目前尚无商业化的RNA聚合酶I或RNA聚合酶II抗体的特异性免疫检测试剂盒可供使用[1, 2]。


    ▶The AC-10 pattern can be seen in various conditions, including systemic sclerosis (SSc), Raynaud’s phenomenon, Sjögren’s disease (SjD), and cancer [1-7]
    ▶If the AC-10 pattern is observed, follow-up testing for NOR90 antibodies is to be considered; the antigen is included in disease specific immunoassays (i.e. SSc profile) [3, 4]
    ▶NOR90 antibody associated with paraneoplastic SSc and with interstitial lung disease in SSc and idiopathic interstitial pneumonia patients [8, 9]
    ▶While AC-10 is seen in sera with RNApol-III antibodies, this is thought to be due to concomitant reactivity with RNApol-I and/or RNApol-II antibodies. RNApol-III antibodies are also associated with mixed AC-4 and AC-5 patterns [10]; therefore, if SSc is clinically suspected, it is recommended to perform a follow-up test for RNApol-III antibodies; specific immunoassays for RNApol-I or RNApol-II antibodies are currently not commercially available [1, 2]
  • 二级信息
    Second level information

  • 无

    None
  • 参考文献
  • 1.Reimer G, Rose KM, Scheer U, Tan EM. Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest. 1987;79:65-72
    2.Kuwana M, Kaburaki J, Mimori T, Tojo T, Homma M. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest. 1993;91:1399-404
    3.Fritzler MJ, von Muhlen CA, Toffoli SM, Staub HL, Laxer RM. Autoantibodies to the nucleolar organizer antigen NOR-90 in children with systemic rheumatic diseases. J Rheumatol. 1995;22:521-4
    4.Fujii T, Mimori T, Akizuki M. Detection of autoantibodies to nucleolar transcription factor NOR 90/hUBF in sera of patients with rheumatic diseases, by recombinant autoantigen-based assays. Arthritis Rheum. 1996;39:1313-8
    5.Imai H, Ochs RL, Kiyosawa K, Furuta S, Nakamura RM, Tan EM. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol. 1992;140:859-70
    6.Lin W, Jia C, Yin H, Lu L. Clinical significance of the anti-Nucleolar Organizer Region 90 antibodies (NOR90) in systemic sclerosis. Eur J Intern Med. 2025;131:159-61
    7.Dima A, Vonk MC, Garaiman A, Kersten BE, Becvar R, Tomcik M, Hoffmann-Vold AM, Castellvi I, et al. Clinical significance of the anti-Nucleolar Organizer Region 90 antibodies (NOR90) in systemic sclerosis: Analysis of the European Scleroderma Trials and Research (EUSTAR) cohort and a systematic literature review. Eur J Intern Med. 2024;125:104-10
    8.Duffau P, Dimicoli S, Gensous N, Truchetet ME, Bordes C. Anti-NOR90 antibody associated with paraneoplastic systemic sclerosis. Clin Exp Rheumatol. 2022;40:2002-3

    9.Yamashita Y, Yamano Y, Muro Y, Ogawa-Momohara M, Takeichi T, Kondoh Y, Akiyama M. Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia. Rheumatology (Oxford). 2022;61:1709-16

    10.Parker JC, Burlingame RW, Webb TT, Bunn CC. Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA. Rheumatology (Oxford). 2008;47:976-9

FAQ